The clinical benefit of prostacyclin treatment in mechanically ventilated patients with SARS-CoV-2 infection is not attributed to anti-inflammatory effects.
CytokineSep 3, 2026 (epub)
Martin Vigstedt, Sarah McGarrity, Peter Søe-Jensen et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial investigated the effects of iloprost on inflammatory and cytokine responses in 80 mechanically ventilated patients with SARS-CoV-2 infection and endotheliopathy. The study found no significant changes in any of the 54 measured biomarkers after 24 hours of treatment, indicating that the clinical benefits of iloprost are not due to anti-inflammatory effects.
Key findings
- Iloprost treatment did not significantly change any of the 54 measured biomarkers at 24 hours.
- No significant effects were identified on any of the six predefined biomarker classes after treatment.
- The study supports that iloprost's clinical benefits are not attributed to anti-inflammatory effects.
Why it matters
Understanding the mechanisms behind treatment effects in critically ill patients is crucial for optimizing therapeutic strategies. This study highlights the need for targeted approaches in managing respiratory failure associated with COVID-19.